EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy

Ian C Smith, Marcos L Sampaio, Gerd Melkus, Kaitlynn Meier-Ross, Shaoni Chakraborty, Cameron Stotts, Pierre R Bourque, Hanns Lochmuller, Bernard Brais, Othmane Ayoub, Theodore J Perkins, Mireille Khacho und 1 weitere

Journal of Neuromuscular Diseases · 2025

DOI: 10.1177/22143602241304990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2025. Verfasst von Ian C Smith und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Oculopharyngeal, Blood Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, slowly progressive neuromuscular disorder characterized by ptosis, dysphagia, and proximal limb weakness. Emerging clinical trials require rapidly accessible and sensitive biomarkers to evaluate OPMD disease progression and potential response to future treatments.

Objective

This cross-sectional study was designed to identify candidate circulating protein and imaging biomarkers of OPMD severity for future use in clinical trials.

Methods

Twenty-five individuals with OPMD (age 63.3 ± 10.5 years; GCN copy number of 13 in PABPN1 ) were assessed using the 7k SOMAScan assay to profile the plasma proteome, and MRI to quantify replacement of muscle by fat. OPMD severity was first categorized using the clinical presence/absence of limb weakness, and protein signals were considered distinguishing if they differed by more than 30% between subgroups and had statistically significant P -values after correcting for multiple comparisons. Distinguishing proteins were contrasted with age-matched controls ( n = 10). OPMD severity was also treated as a continuous variable using fat fraction of the soleus muscle, and proteins were considered distinguishing if the slope of relationship between protein signal and soleus fat fraction differed significantly from zero after correcting for multiple comparisons. Pathway analyses were conducted using Metascape and the Database for Annotation, Visualization, and Integrated Discovery webtools.

Results

Eighteen plasma proteins distinguished OPMD on both indicators of severity. Pathway analyses identified skeletal muscle tissue, phagocytosis/engulfment, and extracellular matrix organization as enriched ontology clusters in OPMD with limb weakness. The most distinguishing plasma protein signals (ACTN2, MYOM2, CA3, APOBEC2, MYL3, and PDLIM3) were over 200% higher in OPMD with limb weakness than OPMD without limb weakness as well as controls, and correlated strongly with percent of fatty replacement of soleus ( r = 0.89 ± 0.04).

Conclusions

The candidate biomarkers identified contribute to the ongoing search for sensitive and accessible biomarkers of OPMD progression, prognosis, and monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, OculopharyngealBlood ProteinsHumansMiddle AgedBiomarkersMaleCross-Sectional StudiesFemaleSeverity of Illness IndexMagnetic Resonance ImagingAgedMuscle, Skeletal

Stichwörter der Autor:innen

accelerated agingbiomarker discoverymuscle MRImuscular dystrophyproteomicsskeletal muscle

Substanzen

BiomarkersBlood Proteins

Autor:innen und Institutionen

  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Eric Poulin Centre for Neuromuscular Disease, University of Ottawa, Ottawa, Ontario, Canada.
  • Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Medical Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Department of Radiology, Radiation Oncology and Medical Physics, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Physics, Carleton University, Ottawa, Ontario, Canada.

Zitieren

APA

Smith, I. C., Sampaio, M. L., Melkus, G., Meier-Ross, K., Chakraborty, S., Stotts, C., Bourque, P. R., Lochmuller, H., Brais, B., Ayoub, O., Perkins, T. J., Khacho, M., & Warman-Chardon, J. (2025). Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602241304990

Vancouver

Smith IC, Sampaio ML, Melkus G, Meier-Ross K, Chakraborty S, Stotts C, et al. Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy. Journal of Neuromuscular Diseases. 2025. doi:10.1177/22143602241304990

BibTeX
@article{Smith2025,
  author = {Smith, Ian C and Sampaio, Marcos L and Melkus, Gerd and Meier-Ross, Kaitlynn and Chakraborty, Shaoni and Stotts, Cameron and Bourque, Pierre R and Lochmuller, Hanns and Brais, Bernard and Ayoub, Othmane and Perkins, Theodore J and Khacho, Mireille and Warman-Chardon, Jodi},
  title = {Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy},
  journal = {Journal of Neuromuscular Diseases},
  year = {2025},
  doi = {10.1177/22143602241304990}
}
Kostenlos starten →